DARTS I: Feasibility, Safety, and Performance Trial
- Conditions
- Acute DeBakey I Aortic DissectionIntramural Hematoma
- Registration Number
- NCT03397251
- Lead Sponsor
- Ascyrus Medical LLC.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 7
Inclusion Criteria:<br><br> 1. Informed Consent obtained<br><br> 2. =18 years of age or =80 years of age (male or female)<br><br> Subject must have one of the following diagnosed, based on CT angiography, within<br> 0-14 days:<br><br> 3. Acute DeBakey I dissection or<br><br> 4. Acute DeBakey I intramural hematoma (IMH)<br><br>Exclusion Criteria:<br><br>General Exclusion Criteria<br><br>Patients must be excluded from the study if any of the following conditions are true:<br><br> 1. Less than 18 years of age or over 80 years of age<br><br> 2. Life expectancy less than 2 years<br><br> 3. Pregnant or breastfeeding or planning on becoming pregnant within 60 months<br><br> 4. Unwilling to comply with the follow-up schedule<br><br> 5. Refusal to give informed consent<br><br> 6. Institutionalized individualized due to administrative or judicial order<br><br> 7. Individuals with a dependent relationship to the sponsor or investigator<br><br>Medical Exclusion Criteria<br><br>Patients must be excluded from the study if any of the following conditions are true:<br><br> 1. Uncontrolled systemic infection<br><br> 2. Uncontrollable anaphylaxis to iodinated contrast<br><br> 3. Known allergy(ies) to Nitinol and/or PTFE<br><br> 4. Patient in extreme hemodynamic compromise requiring cardiopulmonary resuscitation<br> (CPR)<br><br> 5. Inability to obtain CT angiograms for follow-up<br><br> 6. Previously diagnosed with Marfan syndrome, Loeys- Dietz syndrome or Ehlers- Danlos<br> syndrome with confirmed laboratory genetic testing on a date prior to the diagnosis<br> of the dissection<br><br>Anatomical Exclusion Criteria<br><br> 1. Any pathology of mycotic origin<br><br> 2. Subacute or chronic dissection of the ascending aorta and aortic arch (>14 days<br> after the index event)<br><br> 3. Aortic fistulous communication with non-vascular structure (e.g. esophagus,<br> bronchial)<br><br> 4. Extensive thrombus or calcifications in the aortic arch as defined by CT angiography<br><br> 5. Excessive tortuosity precluding safe passage of the AMDS as defined by CT<br> angiography<br><br> 6. Descending thoracic aneurysm involving the proximal third (1/3) of the descending<br> aorta and measuring > 45mm in diameter<br><br> 7. Aortic arch aneurysm > 45mm in diameter
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of participants with treatment-related mortality;Number of participants with treatment-related neurological deficit;Number of patients with aortic injury associated with the implantation of the device;Aortic arch branch vessel patency
- Secondary Outcome Measures
Name Time Method Number of participants with treatment-related mortality;Number of participants with treatment-related neurological deficit;Number of patients with aortic injury associated with the implantation of the device;Aortic arch branch vessel patency